CD274 and neoplasm: Therefore, the circulating exosomal PD‐L1 could be considered as a biomarker for the clinical outcomes of anti‐PD‐1 therapy.125 This was confirmed by another independent study which showed that exosomal PD‐L1 can suppresses T cell function and promotes tumor progression by inducing a systemic immunosuppression.